Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | ABL1 | P00519 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | IDE | P14735 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | HLCS | P50747 | 6/20 | 0.57 |
| ▸ | CA12 | O43570 | 6/20 | 0.44 |
| ▸ | CA1 | P00915 | 6/20 | 0.44 |
| ▸ | CA2 | P00918 | 6/20 | 0.44 |
| ▸ | CA9 | Q16790 | 6/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1527196 | 1.00 | TDP1 (0.58) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL4740139 | 0.99 | TDP1 (0.60) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL425273 | 0.93 | TDP1 (0.67) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL30799994 | 0.91 | HLCS (0.57) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL4466074 | 0.88 | HLCS (0.72) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL1403829 | 0.88 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL5611457 | 0.87 | TDP1 (0.60) | TDP1MEN1ABL1LMNAPKM | |
| Cysteine SCHEMBL8645728 | 0.87 | TDP1 (0.56) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL2350071 | 0.86 | TDP1 (0.60) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL3445951 | 0.86 | TDP1 (0.54) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1578450-A4 | AMPLIFICATION OF BIOTIN-MEDIATED TARGETING | ACCESS PHARMACEUTICALS AUSTRAL (AU) | 2009-06-17 | — | — | EP | disclosed |
| US-20060127310-A1 | Amplification of biotin-mediated targeting | ACCESS PHARMACEUTICALS AUSTRALIA PTY LTD. | 2006-06-15 | — | — | US | disclosed |
| EP-1578450-A1 | AMPLIFICATION OF BIOTIN-MEDIATED TARGETING | Access Pharmaceuticals Australia Pty Ltd (AU) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004045647-A1 | AMPLIFICATION OF BIOTIN-MEDIATED TARGETING | ACCESS PHARMACEUTICALS AUSTRALIA PTY LTD (AU) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060127310-A1 | Amplification of biotin-mediated targeting | BTD, HLCS, SLC1A5 | TDP1 4434/4885MEN1 806/4885ABL1 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.